Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
77.67
Nov 19 • 3:59 PM ET Dollar change+1.72 Percentage change(2.26%)
Aftermarket Close
78.00
Aftermarket • 7:30 PM ET Dollar change+0.33 Percentage change(0.42%)
Index
RUT
Market Cap
3.83B
Enterprise Value
3.61B
Income
-702.23M
Sales
682.20M
Book/sh
2.11
Cash/sh
6.28
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
370
IPO
Oct 16, 2020
P/E
-
Forward P/E
174.50
PEG
-
P/S
5.61
P/B
36.81
P/C
12.37
P/FCF
118.05
EV/EBITDA
-
EV/Sales
5.29
Quick Ratio
1.94
Current Ratio
1.96
Debt/Eq
0.85
LT Debt/Eq
0.85
Option/Short
Yes / Yes
EPS (ttm)
-15.18
EPS next Y
0.45
EPS next Q
-0.28
EPS this Y
-878.20%
EPS next Y
102.86%
EPS next 5Y
-
EPS past 3/5Y
14.26% -3.80%
Sales past 3/5Y
159.54% -
EPS Y/Y TTM
-654.07%
Sales Y/Y TTM
86.34%
EPS Q/Q
-4773.76%
Sales Q/Q
63.92%
Insider Own
5.38%
Insider Trans
-3.72%
Inst Own
101.79%
Inst Trans
9.20%
ROA
-135.04%
ROE
-319.84%
ROIC
-364.42%
Gross Margin
93.21%
Oper. Margin
-9.61%
Profit Margin
-102.93%
SMA20
5.65%
SMA50
4.65%
SMA200
13.86%
Trades
Shs Outstand
49.30M
Shs Float
46.65M
52W High
91.53 -15.14%
52W Low
53.89 44.13%
Volatility
4.93% 5.34%
ATR (14)
3.70
RSI (14)
57.34
Beta
0.33
Rel Volume
0.71
Avg Volume
866.87K
Volume
615,448
Perf Week
1.01%
Perf Month
10.17%
Perf Quarter
6.84%
Perf Half Y
22.35%
Perf YTD
-5.14%
Perf Year
0.73%
Perf 3Y
311.82%
Perf 5Y
209.81%
Perf 10Y
-
Prev Close
75.95
Price
77.67
Change %
2.26%
Consensus
Strong Buy
Avg. Price Target
$102.70
Implied Upside
+32.2%
Analysts11incl. previous ratings
Rating Distribution11 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 24, 2026Resumed
GS logoGGoldman
Buy$116+49.3%
Sep 16, 2026Resumed
BCS logoBBarclays
Overweight$110+41.6%
Apr 24, 2026Resumed
OPY logoOOppenheimer
Outperform$105 → $98+26.2%
Dec 09, 2025Initiated
BCS logoBBarclays
Overweight$100+28.7%
Nov 20, 2025Initiated
MFG logoMMizuho
Outperform$100+28.7%
Jun 02, 2025Resumed
OPY logoOOppenheimer
Outperform$75-3.4%
May 27, 2025Resumed
HH.C. Wainwright
Buy$72-7.3%
Nov 20, 2023Initiated
GS logoGGoldman
Neutral$19-75.5%
Jul 18, 2023Initiated
WWilliam Blair
Outperform$44-43.4%
May 18, 2023Initiated
GGuggenheim
Buy
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Azamian Bobak R.President/CEO and Board ChairNov 13 '26Sale80.3110,000803,100817,991Nov 17 07:00 PM
Bobak AzamianOfficerNov 13 '26Proposed Sale80.1510,000801,500Nov 13 05:00 PM
LINK WILLIAM J PHDDirectorSep 15 '26Sale78.3812,500979,74494,487Sep 17 04:22 PM
WILLIAM J LINKDIRECTORSep 15 '26Proposed Sale78.3812,500979,745Sep 15 04:51 PM
Azamian Bobak R.President/CEO and Board ChairSep 04 '26Sale90.5610,000905,600827,991Sep 09 04:14 PM
Lin Elizabeth YeuChief Medical OfficerSep 04 '26Sale87.5010,773942,6352,547Sep 09 04:13 PM
Lin Elizabeth YeuChief Medical OfficerSep 04 '26Sale87.503,180278,2501,590Sep 09 04:13 PM
Neervannan SeshadriChief Operating OfficerSep 04 '26Sale85.004,564387,94078,532Sep 09 04:12 PM
BOBAK AZAMIANOFFICERSep 04 '26Proposed Sale90.5610,000905,587Sep 04 05:23 PM
Lin Elizabeth YeuMember of immediate family of Sep 04 '26Proposed Sale87.503,180278,250Sep 04 04:03 PM
Lin Elizabeth YeuOfficerSep 04 '26Proposed Sale87.5010,773942,635Sep 04 03:59 PM
Neervannan SeshadriOfficerSep 04 '26Proposed Sale85.004,564387,940Sep 04 03:36 PM
Lin Elizabeth YeuChief Medical OfficerSep 02 '26Sale80.005,387430,96013,320Sep 03 04:29 PM
Lin Elizabeth YeuChief Medical OfficerSep 01 '26Sale73.864,601339,83018,707Sep 03 04:29 PM
Lin Elizabeth YeuChief Medical OfficerSep 02 '26Sale80.001,590127,2004,770Sep 03 04:29 PM
Lin Elizabeth YeuMember of immediate family of Sep 02 '26Proposed Sale80.001,590127,200Sep 02 04:31 PM
Mottiwala AzizFormer OfficerSep 02 '26Proposed Sale81.808,000654,373Sep 02 03:40 PM
Lin Elizabeth YeuOfficerSep 02 '26Proposed Sale80.005,387430,960Sep 02 03:38 PM
BOBAK AZAMIANOFFICERSep 02 '26Proposed Sale80.0610,000800,569Sep 02 02:39 PM
Mottiwala AzizFormer OfficerSep 01 '26Proposed Sale73.9677,6985,746,846Sep 01 04:09 PM
Lin Elizabeth YeuOfficerSep 01 '26Proposed Sale73.864,601339,830Sep 01 02:23 PM
Mottiwala AzizFormer OfficerAug 25 '26Proposed Sale71.8581,3325,843,887Aug 25 04:19 PM
Mottiwala AzizFormer OfficerAug 19 '26Proposed Sale72.0053,0433,819,096Aug 19 02:27 PM
Azamian Bobak R.President/CEO and Board ChairJun 17 '26Sale61.5510,000615,488847,991Jun 22 04:09 PM
Farrow Jeffrey SSee RemarksJun 16 '26Sale60.9514,396877,43656,801Jun 17 04:17 PM
Goodrich KatherineDirectorJun 15 '26Sale62.082,954183,3842,233Jun 17 04:17 PM
LINK WILLIAM J PHDDirectorJun 15 '26Sale62.1212,500776,495106,786Jun 17 04:17 PM
BOBAK AZAMIANOFFICERJun 17 '26Proposed Sale61.5510,000615,473Jun 17 02:05 PM
Farrow Jeffrey SOfficerJun 16 '26Proposed Sale60.9514,396877,459Jun 16 04:53 PM
William J LinkDirectorJun 15 '26Proposed Sale62.1212,500776,498Jun 15 04:58 PM
Goodrich KatherineDirectorJun 15 '26Proposed Sale62.082,954183,384Jun 15 11:44 AM
Neervannan SeshadriChief Operating OfficerMar 20 '26Sale66.752,989199,51682,791Mar 24 05:05 PM
Neervannan SeshadriOfficerMar 20 '26Proposed Sale66.752,989199,516Mar 20 10:38 AM
Whitfield Dianne C.Chief Human Resources OfficerMar 18 '26Sale68.714,071279,71839,202Mar 19 07:04 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 17 '26Sale69.424,029279,69343,273Mar 19 07:04 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 19 '26Sale67.004,174279,65835,028Mar 19 07:04 PM
Wahl BryanGeneral CounselMar 17 '26Sale69.424,084283,51172,315Mar 19 07:04 PM
Wahl BryanGeneral CounselMar 19 '26Sale67.004,231283,47763,959Mar 19 07:04 PM
Wahl BryanGeneral CounselMar 18 '26Sale68.714,125283,42968,190Mar 19 07:04 PM
Neervannan SeshadriChief Operating OfficerMar 19 '26Sale67.004,589307,46385,780Mar 19 07:04 PM
Neervannan SeshadriChief Operating OfficerMar 18 '26Sale68.713,610248,04390,369Mar 19 07:04 PM
Neervannan SeshadriChief Operating OfficerMar 17 '26Sale69.423,125216,93893,979Mar 19 07:04 PM
Mottiwala AzizChief Commercial OfficerMar 17 '26Sale69.424,286297,53470,250Mar 19 07:04 PM
Mottiwala AzizChief Commercial OfficerMar 18 '26Sale68.714,330297,51465,920Mar 19 07:04 PM
Mottiwala AzizChief Commercial OfficerMar 19 '26Sale67.004,440297,48061,480Mar 19 07:04 PM
Lin Elizabeth YeuChief Medical OfficerMar 19 '26Sale67.0039026,13023,308Mar 19 07:04 PM
Lin Elizabeth YeuChief Medical OfficerMar 18 '26Sale68.7137926,04123,698Mar 19 07:04 PM
Lin Elizabeth YeuChief Medical OfficerMar 17 '26Sale69.4237526,03224,077Mar 19 07:04 PM
Farrow Jeffrey SSee RemarksMar 18 '26Sale68.712,133146,55845,502Mar 19 07:03 PM
Farrow Jeffrey SSee RemarksMar 17 '26Sale69.422,111146,54647,635Mar 19 07:03 PM
Farrow Jeffrey SSee RemarksMar 19 '26Sale67.002,186146,46243,316Mar 19 07:03 PM
Azamian Bobak R.President/CEO and Board ChairMar 18 '26Sale68.7111,667801,64045,385Mar 19 07:03 PM
Azamian Bobak R.President/CEO and Board ChairMar 19 '26Sale67.0011,964801,58833,421Mar 19 07:03 PM
Azamian Bobak R.President/CEO and Board ChairMar 17 '26Sale69.4210,972761,67657,052Mar 19 07:03 PM
Farrow Jeffrey SOfficerMar 19 '26Proposed Sale67.002,186146,459Mar 19 04:43 PM
Mottiwala AzizOfficerMar 19 '26Proposed Sale67.004,440297,475Mar 19 04:38 PM
Azamian Bobak R.OfficerMar 19 '26Proposed Sale67.0011,964801,574Mar 19 04:30 PM
Whitfield Dianne C.OfficerMar 19 '26Proposed Sale67.004,174279,653Mar 19 04:24 PM
Wahl BryanOfficerMar 19 '26Proposed Sale67.004,231283,472Mar 19 04:23 PM
Neervannan SeshadriOfficerMar 19 '26Proposed Sale67.004,589307,457Mar 19 04:15 PM
Lin Elizabeth YeuOfficerMar 19 '26Proposed Sale67.0039026,130Mar 19 04:14 PM
Whitfield Dianne C.OfficerMar 18 '26Proposed Sale68.714,071279,718Mar 18 04:33 PM
Wahl BryanOfficerMar 18 '26Proposed Sale68.714,125283,428Mar 18 04:18 PM
Azamian Bobak R.OfficerMar 18 '26Proposed Sale68.7111,667801,637Mar 18 04:17 PM
Neervannan SeshadriOfficerMar 18 '26Proposed Sale68.713,610248,042Mar 18 04:17 PM
Farrow Jeffrey SOfficerMar 18 '26Proposed Sale68.712,133146,558Mar 18 04:14 PM
Mottiwala AzizOfficerMar 18 '26Proposed Sale68.714,330297,513Mar 18 04:13 PM
Lin Elizabeth YeuOfficerMar 18 '26Proposed Sale68.7137926,041Mar 18 04:11 PM
LINK WILLIAM J PHDDirectorMar 16 '26Sale68.7912,500859,819116,332Mar 18 04:11 PM
Azamian Bobak R.OfficerMar 17 '26Proposed Sale69.4110,972761,618Mar 17 04:09 PM
Neervannan SeshadriOfficerMar 17 '26Proposed Sale69.413,125216,921Mar 17 04:07 PM
Farrow Jeffrey SOfficerMar 17 '26Proposed Sale69.412,111146,534Mar 17 04:03 PM
Wahl BryanOfficerMar 17 '26Proposed Sale69.414,084283,490Mar 17 03:59 PM
Whitfield Dianne C.OfficerMar 17 '26Proposed Sale69.414,029279,672Mar 17 03:55 PM
Lin Elizabeth YeuOfficerMar 17 '26Proposed Sale69.4137526,031Mar 17 03:47 PM
Mottiwala AzizOfficerMar 17 '26Proposed Sale69.414,286297,511Mar 17 03:42 PM
WILLIAM J LINKDIRECTORMar 16 '26Proposed Sale68.7812,500859,787Mar 16 05:39 PM
Neervannan SeshadriChief Operating OfficerMar 04 '26Sale76.678,366641,42170,817Mar 05 04:03 PM
Neervannan SeshadriOfficerMar 04 '26Proposed Sale76.678,366641,421Mar 04 10:56 AM
Whitfield Dianne C.Chief Human Resources OfficerJan 02 '26Sale80.6715,5651,255,68423,393Jan 06 04:05 PM
Whitfield Dianne C.OfficerJan 02 '26Proposed Sale81.3815,5651,266,680Jan 02 11:22 AM
Azamian Bobak R.President/CEO and Board ChairDec 24 '25Sale82.516,000495,089857,991Dec 30 04:26 PM
BOBAK AZAMIANOFFICERDec 24 '25Proposed Sale82.516,000495,089Dec 29 12:22 PM
Whitfield Dianne C.Chief Human Resources OfficerDec 16 '25Sale80.107,397592,50038,958Dec 18 04:09 PM
LINK WILLIAM J PHDDirectorDec 15 '25Sale81.4312,5001,017,816128,832Dec 17 04:07 PM
LINK WILLIAM J PHDDirectorDec 15 '25Sale81.0710,446846,8620Dec 17 04:07 PM
Lin Elizabeth YeuChief Medical OfficerDec 16 '25Sale79.502,078165,20121,941Dec 17 04:07 PM
Lin Elizabeth YeuOfficerDec 16 '25Proposed Sale79.502,078165,202Dec 16 03:12 PM
Whitfield Dianne C.OfficerDec 16 '25Proposed Sale80.107,397592,500Dec 16 10:11 AM
William LinkDirectorDec 15 '25Proposed Sale81.0210,446846,340Dec 15 04:38 PM
WILLIAM J LINKDIRECTORDec 15 '25Proposed Sale81.4212,5001,017,800Dec 15 04:08 PM
Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Co-FounderDr. Bobak R. Azamian M.D.
Chief Operating OfficerDr. Seshadri Neervannan Ph.D.
M.D.Dr. Bryan Wahl J.D.
Head of Investor RelationsMr. David Nakasone
Vice President of Corporate CommunicationsMs. Adrienne Kemp